The C terminus of p53 binds the N-terminal domain of MDM2

Nature Structural and Molecular Biology

Volumn 17, Issue 8, 2010, Pages 982-989

  Poyurovsky, Masha V ^a   Katz, Chen ^c   Laptenko, Oleg ^a   Beckerman, Rachel ^a   Lokshin, Maria ^a   Ahn, Jinwoo ^b   Byeon, In Ja L ^b   Gabizon, Ronen ^c   Mattia, Melissa ^d   Zupnick, Andrew ^a   Brown, Lewis M ^a   Friedler, Assaf ^c   Prives, Carol ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NUTLIN 3; PROTEIN MDM2; PROTEIN P53;

ACETYLATION; AMINO TERMINAL SEQUENCE; ANISOTROPY; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DNA BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE DELETION; GENE MUTATION; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; NUCLEAR MAGNETIC RESONANCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION;

ANIMALS; CROSS-LINKING REAGENTS; DNA; HCT116 CELLS; HUMANS; IMIDAZOLES; MASS SPECTROMETRY; MICE; MODELS, BIOLOGICAL; PIPERAZINES; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, SMALL INTERFERING; SEQUENCE DELETION; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77955418479     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb.1872     Document Type: Article

References (56)

1. Vousden, K.H. & Prives, C. Blinded by the light: the growing complexity of p53. Cell 137, 413-431 (2009).
2. Barak, Y., Gottlieb, E., Juven-Gershon, T. & Oren, M. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev. 8, 1739-1749 (1994).
3. Haupt, Y., Maya, R., Kazaz, A. & Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299 (1997).
4. Lin, J., Chen, J., Elenbaas, B. & Levine, A.J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8, 1235-1246 (1994).
5. Kussie, P.H. et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948-953 (1996).
6. Vassilev, L.T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
7. Klein, C. & Vassilev, L.T. Targeting the p53-MDM2 interaction to treat cancer. Br. J. Cancer 91, 1415-1419 (2004).
8. Issaeva, N. et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 10, 1321-1328 (2004).
9. Shieh, S.Y., Ikeda, M., Taya, Y. & Prives, C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91, 325-334 (1997).
10. Appella, E. & Anderson, C.W. Signaling to p53: breaking the posttranslational modification code. Pathol. Biol. (Paris) 48, 227-245 (2000).
11. Kane, S.A. et al. Development of a binding assay for p53/HDM2 by using homogeneous time-resolved fluorescence. Anal. Biochem. 278, 29-38 (2000).
12. Sakaguchi, K. et al. Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase. Effect on Mdm2 binding. J. Biol. Chem. 275, 9278-9283 (2000).
13. Lai, Z., Auger, K.R., Manubay, C.M. & Copeland, R.A. Thermodynamics of p53 binding to hdm2(1-126): effects of phosphorylation and p53 peptide length. Arch. Biochem. Biophys. 381, 278-284 (2000).
14. Shimizu, H. et al. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo. J. Biol. Chem. 277, 28446-28458 (2002).
15. Wallace, M., Worrall, E., Pettersson, S., Hupp, T.R. & Ball, K.L. Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol. Cell 23, 251-263 (2006).
16. Yu, G.W. et al. The central region of HDM2 provides a second binding site for p53. Proc. Natl. Acad. Sci. USA 103, 1227-1232 (2006).
17. Ma, J. et al. A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination. Biochemistry 45, 9238-9245 (2006).
18. Rodriguez, M.S., Desterro, J.M., Lain, S., Lane, D.P. & Hay, R.T. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol. Cell. Biol. 20, 8458-8467 (2000).
19. Carter, S. & Vousden, K.H. Modifications of p53: competing for the lysines. Curr. Opin. Genet. Dev. 19, 18-24 (2009).
20. Carter, S., Bischof, O., Dejean, A. & Vousden, K.H. C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nat. Cell Biol. 9, 428-435 (2007).
21. Li, M. et al. Mono-versus polyubiquitination: differential control of p53 fate by Mdm2. Science 302, 1972-1975 (2003).
22. Tang, Y., Zhao, W., Chen, Y., Zhao, Y. & Gu, W. Acetylation is indispensable for p53 activation. Cell 133, 612-626 (2008).
23. Le Cam, L. et al. E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation. Cell 127, 775-788 (2006).
24. Hainaut, P. et al. IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res. 26, 205-213 (1998).
25. Cho, Y., Gorina, S., Jeffrey, P.D. & Pavletich, N.P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265, 346-355 (1994).
26. Sutherland, B.W., Toews, J. & Kast, J. Utility of formaldehyde cross-linking and mass spectrometry in the study of protein-protein interactions. J. Mass Spectrom. 43, 699-715 (2008).
27. Ahn, J. & Prives, C. The C-terminus of p53: the more you learn the less you know. Nat. Struct. Biol. 8, 730-732 (2001).
28. Cain, C., Miller, S., Ahn, J. & Prives, C. The N terminus of p53 regulates its dissociation from DNA. J. Biol. Chem. 275, 39944-39953 (2000).
29. Poyurovsky, M.V. et al. The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J. 26, 90-101 (2007).
30. McKinney, K., Mattia, M., Gottifredi, V. & Prives, C. p53 linear diffusion along DNA requires its C terminus. Mol. Cell 16, 413-424 (2004).
31. Schon, O., Friedler, A., Bycroft, M., Freund, S.M. & Fersht, A.R. Molecular mechanism of the interaction between MDM2 and p53. J. Mol. Biol. 323, 491-501 (2002).
32. Showalter, S.A., Bruschweiler-Li, L., Johnson, E., Zhang, F. & Bruschweiler, R. Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft. J. Am. Chem. Soc. 130, 6472-6478 (2008).
33. Ding, K. et al. Structure-based design of potent non-peptide MDM2 inhibitors. J. Am. Chem. Soc. 127, 10130-10131 (2005).
34. Garcia-Echeverria, C., Chene, P., Blommers, M.J. & Furet, P. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. J. Med. Chem. 43, 3205-3208 (2000).
35. Duncan, S.J., Cooper, M.A. & Williams, D.H. Binding of an inhibitor of the p53/MDM2 interaction to MDM2. Chem. Commun. (Camb.) 316-317 (2003).
36. Bottger, V. et al. Identification of novel mdm2 binding peptides by phage display. Oncogene 13, 2141-2147 (1996).
37. Vassilev, L.T. Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle 3, 419-421 (2004).
38. Thompson, T. et al. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J. Biol. Chem. 279, 53015-53022 (2004).
39. Ohkubo, S., Tanaka, T., Taya, Y., Kitazato, K. & Prives, C. Excess HDM2 impacts cell cycle and apoptosis and has a selective effect on p53-dependent transcription. J. Biol. Chem. 281, 16943-16950 (2006).
40. de Stanchina, E. et al. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev. 12, 2434-2442 (1998).
41. Stott, F.J. et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17, 5001-5014 (1998).
42. Hay, T.J. & Meek, D.W. Multiple sites of in vivo phosphorylation in the MDM2 oncoprotein cluster within two important functional domains. FEBS Lett. 478, 183-186 (2000).
43. Blattner, C., Hay, T., Meek, D.W. & Lane, D.P. Hypophosphorylation of Mdm2 augments p53 stability. Mol. Cell. Biol. 22, 6170-6182 (2002).
44. McCoy, M.A., Gesell, J.J., Senior, M.M. & Wyss, D.F. Flexible lid to the p53-binding domain of human Mdm2: implications for p53 regulation. Proc. Natl. Acad. Sci. USA 100, 1645-1648 (2003).
45. Ito, A. et al. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 20, 1331-1340 (2001).
46. Kobet, E., Zeng, X., Zhu, Y., Keller, D. & Lu, H. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc. Natl. Acad. Sci. USA 97, 12547-12552 (2000).
47. Wahl, G.M. Mouse bites dogma: how mouse models are changing our views of how P53 is regulated in vivo. Cell Death Differ. 13, 973-983 (2006).
48. Feng, H. et al. Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation. Structure 17, 202-210 (2009).
49. Jenkins, L.M. et al. Two distinct motifs within the p53 transactivation domain bind to the Taz2 domain of p300 and are differentially affected by phosphorylation. Biochemistry 48, 1244-1255 (2009).
50. Gorgoulis, V.G. et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434, 907-913 (2005).
51. Bartkova, J. et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434, 864-870 (2005).
52. Lokshin, M., Li, Y., Gaiddon, C. & Prives, C. p53 and p73 display common and distinct requirements for sequence specific binding to DNA. Nucleic Acids Res. 35, 340-352 (2007).
53. Zhang, T. & Prives, C. Cyclin a-CDK phosphorylation regulates MDM2 protein interactions. J. Biol. Chem. 276, 29702-29710 (2001).
54. Rotem, S. et al. The structure and interactions of the proline-rich domain of ASPP2. J. Biol. Chem. 283, 18990-18999 (2008).
55. Cardinale, C.J. et al. Termination factor Rho and its cofactors NusA and NusG silence foreign DNA in E. coli. Science 320, 935-938 (2008).
56. Beckerman, R. et al. A role for Chk1 in blocking transcriptional elongation of p21 RNA during the S-phase checkpoint. Genes Dev. 23, 1364-1377 (2009).